Norris Medicines Ltd

Board actions

• Un-audited results for quarter ended June 30, 2026 approved with Limited Review Report.
• Vimal Dhirendra Shah appointed Managing Director for 3 years from Sep 1, 2026, subject to shareholder approval.

CFO Appointment

• Type of change: Appointment of CFO and KMP.
• Person: Mr. Iqubal Ismail Patel appointed as Chief Financial Officer.
• Effective date: 30 July 2026.
• Term: On terms including remuneration mutually agreed.
• Profile: 11+ years with Norris Medicines; finance, budgeting, taxation, corporate management.
• Relationship: Not related to Directors or KMP.
• Board/Committee impact: Approved by Audit Committee and Nomination & Remuneration Committees.
• Reason: Appointment as Chief Financial Officer.

Reg 74(5) dematerialisation update

• Compliance certificate confirms dematerialisation for quarter ended June 2026 under Reg 74(5).
• Purva Sharegistry confirms processing and listing on exchanges for dematerialised securities.
• Dematerialisation certificates confirmed or rejected; register of members updated within prescribed timelines.
• RTA provides dematerialised holding details, including shareholder names and demat dates.

🗓️ Meeting Details

• Board meeting scheduled for 14 February 2026 at the registered office in Ankleshwar, Gujarat.

📍 Key Agenda Items

• Approval of unaudited financial results for quarter and nine months ended 31 December 2025 with limited review report.

Management Change

• Mr. Iqubal Patel resigned as Chief Financial Officer and Key Managerial Personnel effective February 3, 2026.
• Resignation due to personal reasons; no other material reasons stated by Mr. Patel.
• Mr. Patel ceases to be KMP under Section 203 of the Companies Act and SEBI LODR Regulations from February 3, 2026.
• Mr. Patel served as CFO since January 2022.
• Company is in process of appointing a new CFO; appointment details pending.